BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
July 06 2022 - 6:00AM
Business Wire
BeiGene and InnoRNA will jointly research a
number of mRNA-LNP programs, and BeiGene will hold exclusive global
development and commercialization rights for the product candidates
from the programs
BeiGene will also gain a non-exclusive
license to InnoRNA’s proprietary LNP Technology to support internal
discovery efforts
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global,
science-driven biotechnology company focused on developing
innovative and affordable medicines to improve treatment outcomes
and access for patients worldwide, today announced it entered into
a worldwide strategic collaboration with InnoRNA, a biotechnology
company with expertise in LNP-based delivery technology and mRNA
drug discovery, to leverage its innovative technology platform for
developing mRNA-based therapeutics.
“As a global biotechnology company, BeiGene is committed to
delivering next-generation therapies through our own internal
discovery engine and leveraging cutting-edge technology from
experienced and innovative partners,” said Lai Wang, Ph.D., Global
Head of R&D at BeiGene. “This collaboration with InnoRNA
advances and supports our research efforts in the important field
of mRNA therapies while securing critical, proprietary delivery
tools.”
Under the terms of the agreement, InnoRNA will receive an
upfront cash payment and will be eligible to receive additional
payments based upon the achievement of certain development,
regulatory, and commercial milestones, as well as tiered royalties,
for the mRNA-LNP research collaboration programs. BeiGene will hold
exclusive global development and commercialization rights for the
mRNA-LNP therapies jointly discovered by InnoRNA and BeiGene.
InnoRNA will receive an additional upfront cash payment and is
eligible for additional milestone payments for granting BeiGene
non-exclusive license to its proprietary LNP Technology
platform.
“We are very excited to partner with BeiGene to discover and
develop innovative mRNA therapies as well as contribute our LNP
technology to BeiGene’s internal research,” said Linxian Li, Ph.D.,
Founder and Chief Executive Officer of InnoRNA. “As evidenced by
the success of multiple Covid-19 vaccines, mRNA and LNPs will
likely play a major role in the future of drug development,
potentially in broad fields beyond vaccines. Joining this
collaboration with BeiGene represents a big step forward toward
this vision for our company.”
About InnoRNA InnoRNA is a platform-based biotechnology
company focused on developing innovative mRNA and LNP technologies
to produce therapeutic proteins rapidly and accurately in cells.
Faced with the challenge of delivering mRNA into the right cells,
the existing carriers have been unable to maximize the potential of
mRNA as a therapeutic tool to generate disease-fighting proteins.
InnoRNA developed the proprietary Diversity-Oriented LNP platform
to deliver mRNA safely and effectively into the cell of interest.
The commercialization of this innovation presents a revolutionary
step towards delivering effective and safe clinical mRNA treatments
for societies everywhere. For more information, please visit our
website at www.innorna.com.
About BeiGene BeiGene is a global, science-driven
biotechnology company focused on developing innovative and
affordable medicines to improve treatment outcomes and access for
patients worldwide. With a broad portfolio of more than 40 clinical
candidates, we are expediting development of our diverse pipeline
of novel therapeutics through our own capabilities and
collaborations. We are committed to radically improving access to
medicines for two billion more people by 2030. BeiGene has a
growing global team of over 8,000 colleagues across five
continents. To learn more about BeiGene, please visit
www.beigene.com and follow us on Twitter at @BeiGeneGlobal.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the plan of future development of mRNA therapies using the licensed
technology; potential payments to InnoRNA, the potential of the
licensed technology; and the parties’ commitments and the potential
benefits of the collaboration, internal discovery and development
plans and BeiGene’s plans, commitments, aspirations and goals under
the heading “About BeiGene.” Actual results may differ materially
from those indicated in the forward-looking statements as a result
of various important factors, including BeiGene's ability to
demonstrate the efficacy and safety of its drug candidates; the
clinical results for its drug candidates, which may not support
further development or marketing approval; actions of regulatory
agencies, which may affect the initiation, timing and progress of
clinical trials and marketing approval; BeiGene's ability to
achieve commercial success for its marketed medicines and drug
candidates, if approved; BeiGene's ability to obtain and maintain
protection of intellectual property for its medicines and
technology; BeiGene's reliance on third parties to conduct drug
development, manufacturing and other services; BeiGene’s limited
experience in obtaining regulatory approvals and commercializing
pharmaceutical products and its ability to obtain additional
funding for operations and to complete the development and
commercialization of its drug candidates and achieve and maintain
profitability; and the impact of the COVID-19 pandemic on BeiGene’s
clinical development, regulatory, commercial, manufacturing, and
other operations, as well as those risks more fully discussed in
the section entitled “Risk Factors” in BeiGene’s most recent
quarterly report on Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in BeiGene's
subsequent filings with the U.S. Securities and Exchange
Commission. All information in this press release is as of the date
of this press release, and BeiGene undertakes no duty to update
such information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220705005854/en/
Investor Contact Kevin Mannix +1 240-410-0129
ir@beigene.com
Media Contact Kyle Blankenship +1 667-351-5176
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jun 2024 to Jul 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Jul 2023 to Jul 2024